Inogen Q3 revenue $84.0M, down 20.3% YoY; GAAP net loss $45.7M from $32.9M impairment

Inogen Inc

2023-Q3 EPS reported -$3.28 revenue$239,764,000

Total revenue $84.0M vs $105.4M in Q3 2022, down 20.3% YoY.
GAAP net loss $45.7M vs $9.5M loss YoY; includes $32.9M non-cash impairment.
Adjusted net loss $8.5M vs $4.1M loss; Adjusted EBITDA loss $5.5M vs $1.2M loss.
Completed acquisition of Physio-Assist SAS, adding airway clearance portfolio.
Cash $138.0M, no debt; focusing on returning to revenue growth.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Inogen Inc reported the quarter ended September 30, 2023 results: revenue $84.0 million, net income GAAP net loss of $45.7 million.

Period: the quarter ended September 30, 2023
Revenue: $84.0 million
Net income: GAAP net loss of $45.7 million
Result: reported results

Exact text from the filing

the homecare setting, today announced financial results for the quarter ended September 30, 2023. Third Quarter 2023 and Recent Business Highlights • Reported total revenue of $84.0 million, reflecting a decrease of 20.3% from the third quarter of 2022. • Completed acquisition of Physio-Assist SAS, expanding Inogen’s global respiratory care presence by addressing a

View on SEC.gov

Browse all earnings releases →

Inogen Inc filing history →

Source: SEC EDGAR

accession 0000950170-23-060245

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.